论文部分内容阅读
目的探讨分析小剂量尿激酶联合扩容治疗急性进展型脑梗死的临床疗效。方法回顾性分析2009年7月至2012年10月间在本院进行治疗的116例急性进展性脑梗死患者的临床记录资料。结果治疗两周后,治疗组总有效率为94.83%,高于对照组的82.76%,差异具有统计学意义(P<0.05);治疗组在治疗一周和两周的NIHSS评分均低于对照组,差异具有统计学意义(P<0.01)。结论小剂量尿激酶联合扩容治疗急性进展型脑梗死的临床疗效显著,可以作为有效的治疗方案而广泛应用。
Objective To investigate the clinical efficacy of low-dose urokinase in combination with expansion to treat acute progressive cerebral infarction. Methods The clinical records of 116 patients with acute progressive cerebral infarction who were treated in our hospital from July 2009 to October 2012 were analyzed retrospectively. Results After two weeks of treatment, the total effective rate of the treatment group was 94.83%, which was higher than that of the control group (82.76%), the difference was statistically significant (P <0.05); NIHSS scores of the treatment group were lower than those of the control group , The difference was statistically significant (P <0.01). Conclusion The combination of low-dose urokinase and dilatation in the treatment of acute progressive cerebral infarction has significant clinical effect and can be widely used as an effective treatment option.